Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)					
As the below na	med inventor(s), I/we declare that:				
This declaration	is directed to:			,	
	☐ The attached application, or				
	Application No, filed on				
	as amended on (if applicable);				
I/we believe that I/sought;	/we am/are the original and first inventor(s) of the subject matter which is	clair	ned and for which a patent	is	
	ed and understand the contents of the above-identified application, includ ifically referred to above;	ling th	ne claims, as amended by	any	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.					
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.					
Full Name of Inventor(s)					
Inventor 1	WADE STANTON BLAIR				
Signature	Weels Rome Citizen	en of	US		
Inventor 2	JOAN QUN CAO				
Signature	Citize	en of	CANADA		
Inventor 3	JASON ISAACSON				
Signature	Citiz	en of	US		
Inventor 4	AMY KAREN PATICK	_			
Signature	Ciny karen Patich Citiz	en of	us		
Additional inventors are being named on					

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** To be assigned Herewith Filing Date **First Named Inventor** WADE STANTON BLAIR DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN POWER OF ATTORNEY Title THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND **CORRESPONDENCE ADDRESS** USES THEREOF INDICATION FORM **Art Unit** To be assigned To be assigned **Examiner Name Attorney Docket Number** PC25522A I hereby appoint: 28940 Practitioners at Customer Number M Practitioners named below: Registration Number Name as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to: M The above-mentioned Customer Number. OR The address associated with Customer Number OR Firm or Individual Name Address Address State Zip City Country Telephone I am the: Applicant/Inventor. \bowtie Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record **WADE STANTON BLAIR** Name Signature 4103 NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

forms are submitted.

☐ *Total of

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** To be assigned

[Filing Date		Herewith			
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS			First Named Inventor		JOAN QUN CAO		
			Title		DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND USES THEREOF		
INDICATION	ON FORM	ľ	Art Unit	***		To be assigned	
		ľ	Examine	r Name		To be assigned	
			Attorney Docket Number		Number	PC25522A	
I hereby appoint:							
Practitioners at Customer Number OR		28940					
Practitioners named b	elow:						
L	Name		Registration		on Number		
					·		
]
as my/our attorney(s) or age business in the United State	nt(s) to prosecute the app s Patent and Trademark (olication Office co	identified a	above, ar nerewith.	nd to transact	all	
Please recognize or change	Please recognize or change the correspondence address for the above-identified application to:						
The above-mentioned Customer Number. OR					!		
The address associated with Customer Number OR							
Firm or Individual Name							_
Address	Address						
Address							
City			s	tate		Zip	
Country							
Telephone			Fa	x			
I am the:	I am the:						
Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name	JOAN QUN CAO						
Signature							
Date	11/04 PO	<u>3</u>					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
□ *Total of forms are submitted.							

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

To be assigned

Herewith

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Filing Date

Application Number

	First Named Inventor		JASON ISAACSON			
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS		Title		DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND USES THEREOF		
INDICAT	INDICATION FORM			To be assigned		
		Examiner N	lame	To be assigned		
		Attorney D	ocket Number	PC25522A		
I hereby appoint:	I hereby appoint:					
Practitioners at Custo	omer Number	28940				
OR	<u> </u>					
Practitioners named	below:					
	Name		Reaistr	ation Number		
as my/our attorney(s) or ago	ent(s) to prosecute the application	n identified abo	ve, and to transa	act all		
	es Patent and Trademark Office c					
_	e the correspondence address for	the above-ide	ntified applicatio	n to:		
The above-mentioned Customer Number.						
OR						
The address associated with Customer Number						
OR						
Firm or Individual Name						
Address						
Address						
City		State		Zip		
Country						
Telephone		Fax				
I am the:						
Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record						
Name	JASON ISAACSON					
Signature						
Date	Date Nov 4 2003					
NOTE: Signatures of all the inveforms if more than one signature	entors or assignees of record of th	ne entire intere	st or their repres	entative(s) are required. Submit multiple		
*Total of forms are su	bmitted.					

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

forms are submitted.

To be assigned

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

		L'	Filing Date		Herewith			
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS			First Named Inventor		AMY KAREN PATICK			
			Title		DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS; IMPROVED LUCIFERASE GENES AND USES THEREOF			
INDICATION	ON FORM	L.	Art Unit			1	ssigned	
			Examine	r Name			ssigned	
			Attorney	Docket N	lumber	PC255	22A	
I hereby appoint:								
Practitioners at Customer Number OR			28940					
Practitioners named b	pelow:							
	Name		$\overline{}$		Registration	on Numi	her	1
					1100.0			1
								ł
as my/our attorney(s) or age business in the United State	ent(s) to prosecute the apples Patent and Trademark C	lication id	dentified a	above, and	to transact	all		•
					application to	o.	· · ·	
The address associated with Customer Number OR								
Firm or Individual Name								
Address								
Address								
City			Str	ate		Zip		
Country								
Telephone			Fax					
I am the:								
Applicant/Inventor.							•	
	the entire interest. See 37 (CFR 3.73(b) is enclosed. (Fo							
SIGNATURE of Applicant or Assignee of Record								
Name	Name AMY KAREN PATICK							
Signature	amyko	aren	· Pa	tick				
Date	<u> </u>	11-	4-03					
NOTE: Signatures of all the inve forms if more than one signature	entors or assignees of record is required, see below*.	rd of the	entire inte	arest or th	eir represen	tative(s) a	re required. Se	ubmit multiple
*Total of forms are submitted.								

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and



Son John

MAY 30, 2003

PTAS

PFIZER, INC. JEFFREY W. RENNECKER 10777 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121 Under Secretary of Commerce For Intellectual Property and Director of the United States Patent and Trademark Office Washington, DC 20231 www.uspto.gov



102350433A

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/28/2003

REEL/FRAME: 013690/0764

NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

BLAIR, WADE STANTON

DOC DATE: 01/13/2003

ASSIGNOR:

CAO, JOAN

DOC DATE: 01/13/2003

ASSIGNOR:

ISAACSON, JASON

DOC DATE: 01/13/2003

ASSIGNOR:

PATICK, AMY KAREN

DOC DATE: 01/13/2003

ASSIGNEE:

AGOURON PHARMACEUTICALS, INC. PATENT PATENT 10777 SCIENCE CENTER DRIVE SAN DIEGO, CALIFORNIA 92121

ASSIGNEE:

PFIZER, INC. 235 EAST 42ND STREET NEW YORK, NEW YORK 10017 013690/0764 PAGE 2

SERIAL NUMBER: 60429382

PATENT NUMBER:

FILING DATE: 11/25/2002

ISSUE DATE:

PAULA MCCRAY, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS



01-29-2003





102350433 Form PTO-1595 RECORD.

(Rev. 6-93)

U.S. DEPARTMENT OF COMMERÇE Patent and Trademark Office Box ASSIGNMENTS

	ÒМ	B No 0651-0011 (exp. 4/94) PATENTS	ONLY	Box ASSIGNMENTS
		To the Honorable Commissioner of Patents and Trademarks:	Please record the attached original document(s) or	r copy thereof.
	1.	Name of conveying party(ies): \'\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Name and address of receiving party(ies): Name: Agouron Pharmaceuticals, Inc. Internal Address: Patent Department	
-	Ad	ditional name(s) of conveying party(ies) attached? Yes No		
	3.	Nature of Conveyance: ☐ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other	and the second s	92151 ≥ Yest □ No
	4.	Application number(s) or patent number(s): If this document is being filed together with a new application A. Patent Application No.(s) 60/429,382 Additional numbers attached	B. Patent No.(s)	AM III: 33
	5.	Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents inv	/olved: 1
		Name: Jeffrey W. Rennecker	7. Total fee (37 CFR 3.41)	40.00
		Internal Address: Pfizer, Inc. Street Address: 10777 Science Center Drive	☐ Enclosed ☐ Authorized to be charged to deposit acc	count
		City: San Diego State: CA ZIP: 92121	8. Deposit account number: 500329 (Attach duplicate copy of this page if paying by	deposit account)
		DO NOT US	E THIS SPACE	
	9.	Statement and signature. To the best of my knowledge and belief, the foregoing informative copy of the original document. Jeffrey W. Rennecker (Reg. 40,784) Name of Person Signing Total number of pages including cover significant cover signif	Signature Signature Da	21, 2003
- 1.	/ へ			

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents & Trademarks, Box Assignments

29/2003 LMUELLER 00000055 500329 60429382

Washington, D.C. 20231

01 FC:8021

40.00 CH

2. Name of receiving party(ies): (Continued)

Pfizer Inc.

Street Address: 235 East 42nd Street

City: New York State: NY ZIP: 10017

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Wade Stanton Blair of 1022 Cima Drive, San Marcos, CA 92069; Joan Cao of 6115 Paseo Jaquita, Carlsbad CA, 92009; Jason Isaacson of 11275 Affinity Court. #120, San Diego, CA 92131; and Amy Karen Patick of 2239 Cortina Circle, Escondido, CA 92029-5545, respectively, hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No. PC25522US, entitled "DUAL ASSAY FOR EVALUATING ACTIVITY AND CYTOTOXICITY OF COMPOUNDS IN THE SAME POPULATION OF CELLS," filed in the United States Patent and Trademark Office on November 25, 2002 and assigned application number 60/429,382, and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of America; and the right to claim priority from said provisional patent application under

the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC. and said PFIZER INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed and witnessed this/3	day of Jan.	2003 at
San Digo CA USA		
J	, 1 , (2 Pm
	(Icul)	5/8
	Wade Stanton Bla	if '
In the presence of:		
Danill Digon)	
Danielle Dixon		
[print name here, sign above]		
	Jan.	
Signed and witnessed this 13	day of えの	3 at
Signed and witnessed this 13 San Diego, CA,	usA.	
	Cr	7
	Joan Cao	
In the presence of:		•
Danille Dyon		
Danielle Dixon		
[print name here, sign above]		

Signed and witnessed this 13 th	day of January, 2003 at				
San Diego	CA USA				
<i>,</i>					
	Jason Isaaoson				
	Jason Isaaoson				
In the presence of:					
Eanille Digon					
Danielle Dixon					
[print name here, sign above]					
Signed and witnessed this	usa January 2003 at				
San Diego, CA	NSA				
V	Amy Karen Patick				
	Amy Karen Patick				
In the presence of:					
S. F.	_ 				
Jules Beardsleig					
[print name here, sign above]					